+1 (704) 266-3234

Rheumatoid Arthritis Testing - Asia-Pacific Analysis And Market Forecasts

Published on: Jun 2016 | From USD $4450 | Published By: GLOBAL DATA | Number Of Pages:

Rheumatoid Arthritis Testing - Asia-Pacific Analysis and Market Forecasts

Summary

The Asia-Pacific (APAC) rheumatoid arthritis (RA) testing market is a dynamic market that is expected to grow through 2022. The rising prevalence of RA, increase in healthcare expenditure globally, rapidly rising demand for autoimmune disease diagnostics, coupled with advancement in technology and the introduction of new tests for example the second generation anti-cyclic citrullinated peptide (anti-CCP) immunoassays and the point of care (POC) lateral flow assays for RA diagnosis, are some of the major factors expected to drive market growth during the forecast period. In addition, the increasing adoption of automated systems as a more cost-effective alternative to manual testing will lead to an increase in the volume of RA tests performed in the APAC markets. Also the implementation of initiatives aimed at developing effective diagnostic and therapeutic solutions for RA will further push for the development of suitable biomarkers.

While RA testing is one of the most lucrative segments within autoimmune testing, the market growth of RA testing will be hampered by the high rate of false positive results and the pressure for healthcare providers to control cost. Moving forward, in light of increasing demand for RA testing, manufacturing companies are racing to develop the next-generation RA biomarkers that are have greater clinical accuracy. A diagnostic test or a multi-biomarker panel that is capable of ruling out RA would be the ultimate goal for manufacturers.

The RA testing market in the APAC region is determined for five major APAC markets: Japan, China, India, Australia, and South Korea. This report provides insight into the adoption trends, market dynamics, competitive landscape, marketed and pipeline products, current and emerging players, as well as market outlooks. The report identifies the unmet needs in the market while providing an understanding of physicians’ perceptions in using and evaluating the adoption of different types of RA diagnostic tests.

*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.

Highlights

Key Questions Answered

- What is the current and future RA testing market outlook in the developed and emerging markets? What trends are affecting the APAC market?
- What is the competitive landscape and who are major players in the RA testing space?
- What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs with the RA tests currently on the market? How will emerging technologies such as POC assays fulfil these unmet needs?
- What are the key products and pipelines in the RA testing market?
- What are the challenges and barriers that have hindered widespread adoption of RA tests in different regions?

Reasons to buy

- “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Key Metrics in Major Markets
2.2 Market Dynamics
2.3 Key Players in the Rheumatoid Arthritis Testing Market
2.4 Rheumatoid Arthritis Testing Market Future Outlook
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Market Access
4.1 Rheumatoid Arthritis Testing Overview
4.2 Reimbursement Trends
4.2.1 Australia
4.2.2 China
4.2.3 India
4.2.4 Japan
4.2.5 South Korea
4.3 Mergers, Acquisitions, and Key Partnerships
5 Unmet Needs
5.1 Earlier Diagnosis
5.2 Seronegativity and Sensitivity
5.2.1 Rheumatoid Factor
5.2.2 Anti-Cyclic Citrullinated Peptide Antibody
5.2.3 14-3-3?
5.3 Novel Biomarkers for Rheumatoid Arthritis Diagnosis
6 Competitive Assessment
6.1 Company Share Analysis
6.1.1 Global
6.2 Abbott Diagnostics
6.2.1 Overview
6.2.2 Marketed Products Assessment
6.2.3 SWOT Analysis
6.3 Beckman Coulter
6.3.1 Overview
6.3.2 Marketed Products Assessment
6.3.3 Pipeline Products Assessment
6.3.4 SWOT Analysis
6.4 Bio-Rad Laboratories
6.4.1 Overview
6.4.2 Marketed Products Assessment
6.4.3 SWOT Analysis
6.5 Euro-Diagnostica
6.5.1 Overview
6.5.2 Marketed Products Assessment
6.5.3 SWOT Analysis
6.6 Inova Diagnostics
6.6.1 Overview
6.6.2 Marketed Products Assessment
6.6.3 SWOT Analysis
6.7 Quest Diagnostics
6.7.1 Overview
6.7.2 Marketed Products Assessment
6.7.3 SWOT Analysis
6.8 F. Hoffmann-La Roche
6.8.1 Overview
6.8.2 Marketed Products Assessment
6.8.3 SWOT Analysis
6.9 Siemens Healthcare
6.9.1 Overview
6.9.2 Marketed Products Assessment
6.9.3 Pipeline Products Assessment
6.9.4 SWOT Analysis
6.10 SQI Diagnostics
6.10.1 Overview
6.10.2 Marked Products Assessment
6.10.3 SWOT Analysis
6.11 Thermo Fisher Scientific
6.11.1 Overview
6.11.2 Marketed Products Assessment
6.11.3 Pipeline Products Assessment
6.11.4 SWOT Analysis
6.12 Other Companies
7 Market Outlook
7.1 Test Trends
7.1.1 Rheumatoid Factor Testing
7.1.2 Anti-Cyclic Citrullinated Peptide Antibody Testing
7.1.3 C-Reactive Protein Testing
7.2 Market Dynamics
7.2.1 Driver: Increasing Anti-CCP Antibody Testing
7.2.2 Driver: Innovative Tests for Rheumatoid Arthritis
7.2.3 Driver: Rising Demand for Lab Automation
7.2.4 Driver: Rising Prevalence of Rheumatoid Arthritis
7.2.5 Barrier: Limited Sensitivity of Existing Tests
7.2.6 Barrier: Healthcare Cost-Cutting
7.3 Market Outlooks by Segment
7.3.1 APAC Overview
7.3.2 Rheumatoid Factor Tests
7.3.3 Anti-Cyclic Citrullinated Peptide Antibody Tests
7.3.4 C-Reactive Protein Tests
7.4 Market Outlooks by Geography
7.4.1 APAC Overview
7.4.2 Japan
7.4.3 Australia
7.4.4 China
7.4.5 India
7.4.6 South Korea
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Report Methodology
8.3.1 Overview
8.3.2 Coverage
8.3.3 Secondary Research
8.3.4 Forecasting Methodology
8.3.5 Primary Research - Key Opinion Leader Interviews
8.3.6 Primary Research - Physician and Industry Interviews
8.3.7 Expert Panel Validation
8.4 About the Team
8.4.1 Analysts
8.4.2 David Brady, Director of Operations - Market Research
8.4.3 Tyler Fletcher, Global Head of Medical Devices
8.5 About MediPoint
8.6 About GlobalData
8.7 Contact Us
8.8 Disclaimer

1.2 List of Figures
Figure 1: Rheumatoid Arthritis Testing Market Revenue, by Major Market, 2015 and 2022
Figure 2: Global RA Testing Market, By Company Share, 2015
Figure 3: APAC RF Test Volume Forecast (thousands) by Country, 2013-2022
Figure 4: APAC RF Test Volume Share Forecast (%) by Country, 2015 and 2022
Figure 5: APAC Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022
Figure 6: APAC Anti-CCP Antibody Test Volume Share Forecast (%) by Country, 2015 and 2022
Figure 7: APAC CRP Test Volume Forecast (thousands) by Country, 2013-2022
Figure 8: APAC CRP Test Volume Share Forecast (%) by Country, 2015 and 2022
Figure 9: APAC Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 10: APAC Rheumatoid Arthritis Analyzer Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 11: APAC Rheumatoid Arthritis Manual Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 12: APAC Rheumatoid Arthritis Testing Market Potential by Test, 2022
Figure 13: RF Marker Tests Sales Forecast ($m) by Country, 2013-2022
Figure 14: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Country, 2013-2022
Figure 15: CRP Marker Test Sales Forecast ($m) by Country, 2013-2022
Figure 16: APAC Rheumatoid Arthritis Testing Sales Forecast ($m), 2013-2022
Figure 17: APAC Rheumatoid Arthritis Testing Market Share Forecast (%) by Country, 2015 and 2022
Figure 18: APAC Rheumatoid Arthritis Testing Market Potential by Country, 2022
Figure 19: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 20: Japan Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 21: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 22: Australia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 23: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 24: China Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 25: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 26: India Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 27: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 28: South Korea Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 29: Rheumatoid Arthritis Testing - Primary Call Count by Country (N=75)

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $4450
USD $8900
USD $11645
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.